10Apr/14

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are … – PR Newswire (press release)

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are
PR Newswire (press release)
It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, …

and more »

10Apr/14

Billingham PCSO Lindsey Blackburn organises six events to help beat blood … – Gazette Live


Gazette Live

Billingham PCSO Lindsey Blackburn organises six events to help beat blood
Gazette Live
But a stem cell transplant from her brother Stephen in April 2011 did the trick and three years on, she’s still in remission. Linda, 28, who has been a PCSO for more than six years and currently patrols in Billingham, said: “You have difficult days

and more »

10Apr/14

Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock … – Wall Street Journal

Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock
Wall Street Journal
We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, …

and more »

10Apr/14

Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR … – GlobeNewswire (press release)

Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR
GlobeNewswire (press release)
SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, …
Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene TherapyXconomy
Celladon Gets Breakthrough Therapy Designation For Mydicar From FDARTT News

all 5 news articles »